Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Evaluate the Safety of Donepezil Hydrochloride((Aricept®) for up to 1 Year in the Treatment of Cognitive Dysfunction Exhibited by Children With Down Syndrome-Follow-up to a 10-Week,Double-Blind,Placebo-Controlled Trial

NCT00675025 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00675025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00675025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Evaluate the Safety of Donepezil Hydrochloride((Aricept®) for up to 1 Year in the Treatment of Cognitive Dysfunction Exhibited by Children With Down Syndrome-Follow-up to a 10-Week,Double-Blind,Placebo-Controlled Trial
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 4, 2008
Completion date
December 15, 2008
Enrollment
117 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome